Hyperthermia in the Treatment of Post-Actinic Osteosarcomas: Our Anecdotal Experience

Tancredi, Antonio; Ciuffreda, Luigi; Cuttitta, Antonello; Scaramuzzi, Roberto; Sabatino, Rosanna; Scaramuzzi, Gerardo
August 2011
Eurasian Journal of Medicine;Aug2011, Vol. 43 Issue 2, p115
Academic Journal
Case Study
Irradiation-induced sarcomas are a late sequelae of irradiation therapy. Most sarcomas have been reported to occur after exposure to a radiation dose of 55 Gys and above, with a dose ranging from 16 Gys to 112 Gys. These tumours are very aggressive and an early detection is needed for a timely intervention. Surgery is only effective treatment for local control instead chemotherapy is a valuable tool for systemic control of disease. Irradiation therapy use is controversial because of its side effects on a site previously irradiated. Irradiation therapy combined with hyperthermia is a new treatment that overcomes these problems without limiting the effect of radiation therapy. It may become a tool for local control of the unresectable tumours or an adjuvant treatment of the surgery. In this report we present a rare case of irradiation-induced recurrent osteosarcoma involving the chest wall that was treated with surgical resection followed by radiation therapy combined with hyperthermia as an adjuvant treatment of the surgery.


Related Articles

  • FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients. Rousseau, Caroline; Devillers, Anne; Campone, Mario; Campion, Loïc; Ferrer, Ludovic; Sagan, Christine; Ricaud, Myriam; Bridji, Boumédiène; Kraeber-Bodéré, Fran&a#x00E7;oise // European Journal of Nuclear Medicine & Molecular Imaging;Jun2011, Vol. 38 Issue 6, p1029 

    Purpose: Regional axillary lymph node status has remained the single most independent variable to predict prognosis both in terms of disease recurrence and survival. This study aimed to prospectively assess sequential [F]fluorodeoxyglucose (FDG) positron emission tomography (PET) findings as...

  • Clinical Cancer Research.  // Biomedical Market Newsletter;8/23/2011, Vol. 21, p178 

    The article offers information on the feasibility of serial positron emission tomography (PET) scanning implementation in testing the efficiency of estrogen-blocking drugs in breast cancer patients, as demonstrated by the Seattle Cancer Care Alliance.

  • Widespread subcutaneous metastases in a patient with breast cancer: Evaluation with fluoro deoxy-glucose positron emission tomography-computed tomography. Balasubramanian Harisankar, Chidambaram Natrajan // Indian Journal of Nuclear Medicine;Jul2013, Vol. 28 Issue 3, p190 

    A letter to the editor related to a case study of 47-year-old female with breast cancer who was diagnosed with 8 fluoride–fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in the previous issue is presented.

  • FDG PET/CT for monitoring response to neoadjuvant chemotherapy in breast cancer patients. Dalus, Katharina; Rendl, Gundula; Rettenbacher, Lukas; Pirich, Christian // European Journal of Nuclear Medicine & Molecular Imaging;Oct2010, Vol. 37 Issue 10, p1992 

    A letter to the editor is presented in response to the previously published study "FDG PET/CT for monitoring response to neoadjuvant chemotherapy in breast cancer patients."

  • Going for a Third Opinion.  // Good Housekeeping;Oct2008, Vol. 247 Issue 4, p46 

    The article presents a case study of a woman Kim Friedrich suffering with breast cancer. In February 2007, her left breast had a tumor, the surgeon told her she needed to have that breast removed, as well as the other as a precaution. She wasn't convinced she had to lose her breasts. She visited...

  • Microenvironment: Domino effect. Seton-Rogers, Sarah // Nature Reviews Cancer;Aug2012, Vol. 12 Issue 8, p506 

    The article discusses which identifies the paracrine signaling network between stromal and tumour cells that may drive the resistance and metastasis of breast cancer patients to chemotherapy.

  • Therapeutic Usefulness of Postoperative Adjuvant Chemotherapy with Tegafur--Uracil (UFT) in Patients with Breast Cancer: Focus on the Results of Clinical Studies in Japan. NAKAYAMA, TAKAHIRO; NOGUCHI, SHINZABURO // Oncologist;Jan2010, Vol. 15 Issue 1, p26 

    In Japan, the history of postoperative chemotherapy for breast cancer started with 5-fluorouracil (5-FU), launched in the 1980s. Currently, oral fluoropyrimidine-based regimens indicated for the treatment of breast cancer in Japan include tegafur plus uracil (UFT); tegafur, gimeracil, and...

  • Marijuana component could ease pain from chemotherapy drugs.  // Biomedical Market Newsletter;10/10/2011, Vol. 21, p161 

    The article reports that the onset of pain linked with drugs used in chemotherapy particularly in patients with breast cancer could be prevented by a chemical component of the marijuana plant.

  • Journal of Proteomics: Biomarker family found for chemo resistant breast cancers.  // Biomedical Market Newsletter;4/14/2012, Vol. 21, p1 

    The article informs that scientists from the University of Hull, Hull, England have discovered biomarkers which could help to predict resistance to chemotherapy in breast cancer patients.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics